CN100446759C - Gastrodine tablets disintegrating in oral cavity and process for producing same - Google Patents
Gastrodine tablets disintegrating in oral cavity and process for producing same Download PDFInfo
- Publication number
- CN100446759C CN100446759C CNB2006101405208A CN200610140520A CN100446759C CN 100446759 C CN100446759 C CN 100446759C CN B2006101405208 A CNB2006101405208 A CN B2006101405208A CN 200610140520 A CN200610140520 A CN 200610140520A CN 100446759 C CN100446759 C CN 100446759C
- Authority
- CN
- China
- Prior art keywords
- gastrodine
- parts
- oral cavity
- microcapsule
- disintegrating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention relates to a gastrodine mouse mouse disintegration tablet, which uses gastrodine as main drug, with gastrodine coat capsule, diluter, and disintegrator. Wherein, the invention is characterized in that: said capsule is made from gastrodine, coated by acrylic acid resin and acrylic acid; and the disintegrator is low-replace hydroxypropyl cellulose and crosslink polyvinyl pyrrolidon. The invention has better disintegration time limit, with uniform solution.
Description
Technical field
The present invention relates to a kind of gastrodine tablets disintegrating in oral cavity and preparation method thereof.Gastrodine has calmness, convulsion, epilepsy, analgesia; the cerebral blood flow increasing amount is improved vertebra basilar artery, posterior inferior cerebellar artery, posterior inferior cerebellar artery, labyrinthine artery and in ear blood supply insufficiency, the neuroprotective cell; promote the function of myocardial cell energy metabolism, be wide clinical application.Belong to field of medicaments.
Background technology
Gastrodine is the main component of rare medicinal herbs Rhizoma Gastrodiae; have calmness, convulsion, epilepsy, analgesia; the cerebral blood flow increasing amount; improve vertebra basilar artery, posterior inferior cerebellar artery, posterior inferior cerebellar artery, labyrinthine artery and in ear blood supply insufficiency; the neuroprotective cell; promote the function of myocardial cell energy metabolism, and be wide clinical application.This product mainly is applicable to dizzy (Meniere, poison of drug vertigo, vestibular neuronitis, vertebro-basilar artery insufficiency etc.), the auxiliary treatment of neuralgia (trigeminal neuralgia, sciatica, neuralgia of greater occipital nerve), headache (neurasthenia and neurasthenia syndrome, the headache of blood vessel character, tension headache, combined external head injuries, migraine etc.) and epilepsy.
The gastrodine common dose is 150-300mg every day, and weight person can increase to 400mg.Untoward reaction is slight, have a few patients symptoms such as mouth and nose drying, giddy, stomach upset to occur, but the unlikely patient of influence accepts medication, also need not special handling.
The dosage form that gastrodine is commonly used clinically has at present: gastrodini: 25mg, 50mg; Capsule: 25mg/ grain, 50mg/ grain; Injection: 1ml:0.1g, 2ml:0.2g.Simultaneously, also has the appearance of products such as acegastrodine sheet, synthetic gastrodini.The oral solid formulation of gastrodine needs water to swallow when taking, and this has brought many inconveniences to busy patient or the inconvenient patient of function of deglutition etc., has reduced the compliance of patient treatment.
For further enriching gastrodine pharmaceutical preparation kind, for clinical application provides more selection, also be convenient to some old peoples, child or swallow patient's medication that medicine has obstacle simultaneously, gastrodine is developed into oral cavity disintegration tablet, significant.
Summary of the invention
For this reason, the object of the invention aims to provide a kind of gastrodine tablets disintegrating in oral cavity and preparation method thereof.Technical scheme of the present invention is as follows:
The invention provides a kind of gastrodine tablets disintegrating in oral cavity, with gastrodine as principal agent, comprise gastrodine dressing microcapsule, diluent and disintegrating agent, it is characterized in that described gastrodine dressing microcapsule is is the microcapsule that coating material is prepared from by gastrodine with acrylic resin and ethyl cellulose, and described disintegrating agent is low-substituted hydroxypropyl cellulose and crospolyvinylpyrrolidone.
Wherein, above-mentioned described acrylic resin can be polyacrylic resin I, II, III, IV, and
The acrylic resin of series.As optimal way of the present invention, select for use polyacrylic resin IV and
NE30D.
The preparation method of microcapsule can be prepared with microcapsule preparation technology conventional in this area.For example adopt air suspension to be prepared.As making the gastrodine dressing microcapsule by the following method:
1. with polyacrylic resin IV,
The adequate amount of ethanol that is dissolved in NE30D and ethyl cellulose fully stirs and makes dissolving, and is standby as the capsule material;
2. the micropowder silica gel mix homogeneously of gastrodine and recipe quantity places fluid bed, adopts air suspension to prepare microcapsule;
3. the gastrodine microcapsule for preparing is crossed the 0.60mm screen cloth and sieve, promptly.
Above-mentioned described gastrodine tablets disintegrating in oral cavity, the proportioning of disintegrating agent low-substituted hydroxypropyl cellulose and crospolyvinylpyrrolidone wherein, can be as required determine by test that suitable proportioning, the present invention are preferably and calculate 1: 1～2 by weight, more preferably 3: 4.
Wherein, above-mentioned described diluent is not particularly limited, can be the diluent of routine, for example be in mannitol, xylitol, sorbitol, maltose, microcrystalline Cellulose, polymerization sugar, glucose, lactose, sucrose, dextrin, the starch one or more; The present invention is preferably mannitol and microcrystalline Cellulose.
The consumption of diluent can be determined suitable consumption by routine test, has after suitable disintegration, the disintegrate state and takes mouthfeel to guarantee prepared oral cavity disintegration tablet.Preferred its consumption of the present invention be account for sheet heavy 30%～70%; More preferably 50%.
The above-mentioned described gastrodine tablets disintegrating in oral cavity of the present invention wherein, if desired, can also contain binding agent, correctives, lubricant, fluidizer or effervescent.
Wherein, described binding agent can be binding agent conventional on the pharmaceutics, for example one or more in starch, pregelatinized Starch, dextrin, maltodextrin, sucrose, arabic gum, methylcellulose, carboxymethyl cellulose, ethyl cellulose, polyvinyl alcohol, Polyethylene Glycol, polyvinylpyrrolidone, PVP-K30, alginic acid or alginate, xanthan gum, the hydroxypropyl emthylcellulose;
Wherein, described correctives can be correctives conventional on the pharmaceutics, for example is in mannitol, xylitol, stevioside, lactose, fructose, sucrose, protein sugar, maltose alcohol, glycyrrhizin, Sodium Cyclamate, gelatin, aspartame, flavoring banana essence, flavoring pineapple essence, vanillin, fragrant citrus essence, withered sub-essence, Herba Menthae essence, ginseng essence, strawberry essence, citric acid, the citric acid one or more;
Described fluidizer can be a fluidizer conventional on the pharmaceutics, for example is in micropowder silica gel, Pulvis Talci, the hydrated sodium aluminosilicate one or more;
Described lubricant can be lubricant conventional on the pharmaceutics, for example is in magnesium stearate, calcium stearate, zinc stearate, glyceryl monostearate, Polyethylene Glycol, hydrogenated vegetable oil, sodium stearyl fumarate, polyoxyethylene monostearate, single Laurel sucrose acid ester, sodium laurylsulfate, magnesium laurylsulfate, Stepanol MG and the Pulvis Talci one or more;
Described effervescent for example can be the mixture of malic acid, citric acid or citric acid and sodium bicarbonate or sodium carbonate.
The consumption of above-mentioned adjuvant can be determined by suitable test according to the needs of preparation, and this is conventional or general technology for a person skilled in the art.
Another purpose of the present invention provides a kind of method for preparing above-mentioned described gastrodine tablets disintegrating in oral cavity, it is characterized in that comprising the steps: that (1) gastrodine is that coating material is made the gastrodine dressing microcapsule with acrylic resin and ethyl cellulose; (2) gastrodine dressing microcapsule and all the other component mix homogeneously carry out tabletting.
Wherein, above-mentioned described acrylic resin can be polyacrylic resin I, II, III, IV, and
The acrylic resin of series.As optimal way of the present invention, select for use polyacrylic resin IV and
NE30D.
The preparation method of microcapsule can be prepared with microcapsule preparation technology conventional in this area.For example adopt air suspension to be prepared.As making the gastrodine dressing microcapsule by the following method:
1. with polyacrylic resin IV,
The adequate amount of ethanol that is dissolved in NE30D and ethyl cellulose fully stirs and makes dissolving, and is standby as the capsule material;
2. the micropowder silica gel mix homogeneously of gastrodine and recipe quantity places fluid bed, adopts air suspension to prepare microcapsule;
3. the gastrodine microcapsule for preparing is crossed the 0.60mm screen cloth and sieve, promptly.
In the above-mentioned described method, in the wherein said step (2), preferred diluent is mixed with gastrodine dressing microcapsule and other component after making granule with binding agent again.
Oral cavity disintegration tablet of the present invention, be to reduce along with the increase of pressure its disintegration substantially, and pressure is excessive to influence disintegrate, and too small then slice, thin piece is frangible.Those skilled in the art can determine the pressure that the present invention is suitable by routine test, and as of the present invention preferred, pressure is 2～5N/kg, more preferably 3～4N/kg.
As the present invention's one specific embodiments, described gastrodine tablets disintegrating in oral cavity wherein, calculates by weight, 50 parts of gastrodine, and 10 parts of polyacrylic resin IV,
1 part of NE30D, 10 parts of ethyl celluloses, 6 parts of low-substituted hydroxypropyl celluloses, 8 parts of crospolyvinylpyrrolidone, 80 parts in mannitol, 10 parts of microcrystalline Cellulose, 5.4 parts of micropowder silica gels, 2 parts of aspartames, 2 parts of flavoring orange essences, 1.5 parts of magnesium stearate, each is an amount of for PVP-K30 and ethanol, and makes by the following method: 1. polyacrylic resin IV,
NE30D and ethyl cellulose are dissolved in ethanol, make coating solution; 2. gastrodine and micropowder silica gel mix homogeneously are made the gastrodine dressing microcapsule with above-mentioned coating solution; 3. mannitol is made mannitol particles with PVP-K30 as binding agent; 4. the above-mentioned gastrodine dressing microcapsule that makes, mannitol particles and remaining component uniform mixing carry out tabletting.
The gastrodine tablets disintegrating in oral cavity of the present invention by preparing after selecting for use suitable disintegrants and gastrodine to handle in a suitable manner, has good disintegration, and granule is in small, broken bits after the disintegrate, and is molten diffusing rapid, even, meets the specification requirement of oral cavity disintegration tablet fully.In addition, the operability of technology is good, is fit to commercial production.The resulting oral cavity disintegration tablet of the present invention, do not need when taking water just can be in the oral cavity disintegrate rapidly, for old man, infant and be busy with one's work, patient anhydrous or water intaking inconvenience provides great convenience; Compare with common oral preparation, extensively covered by the oral fast solubility preparation because of gastrointestinal tract mucous, can reach effective blood drug level sooner, onset is rapid; The suitable adjuvant that adds correctives or cover bad smell uses compliance thereby improve the patient in prescription.
The specific embodiment
Further explain and describe purport of the present invention by the following examples, but it does not constitute the restriction to claim protection domain of the present invention.
Embodiment 1: gastrodine tablets disintegrating in oral cavity
1. preparation prescription
Gastrodine 50.0g
Polyacrylic resin IV 10.0g
NE30D 1.0g
Ethyl cellulose 10.01g
Differential silica gel 5.4g
Low substituted hydroxy-propyl fiber 6.0g
Crospolyvinylpyrrolidone 8.0g
Microcrystalline Cellulose 10.0g
Mannitol 80.0g
Aspartame 2g
Flavoring orange essence 2g
Magnesium stearate 1.5g
PVP-K30 is an amount of
Alcoholic solution is an amount of
Make 1000
2. prescription is formed explanation
Gastrodine: principal agent
Polyacrylic resin IV,
NE30D, ethyl cellulose: coating material
Differential silica gel: fluidizer
Mannitol, microcrystalline Cellulose: diluent
Low substituted hydroxy-propyl fiber, crospolyvinylpyrrolidone: disintegrating agent
Aspartame, flavoring orange essence: correctives
Magnesium stearate: lubricant
3. preparation method
(1) preparation method of gastrodine dressing microcapsule:
1. with polyacrylic resin IV,
The adequate amount of ethanol that is dissolved in NE30D and ethyl cellulose fully stirs and makes dissolving, and is standby as the capsule material;
2. the micropowder silica gel mix homogeneously of gastrodine and recipe quantity places fluid bed, adopts air suspension to prepare microcapsule;
3. the gastrodine microcapsule for preparing is crossed the 0.60mm screen cloth and sieve, standby.
(2) preparation of mannitol particles: get the mannitol of recipe quantity, with 2%PVP-K30 alcoholic solution system soft material, mistake 30 mesh sieves, wet granular is at 55 ℃ of dryings 1 hour, granulate.
(3) low substituted hydroxy-propyl fiber, crospolyvinylpyrrolidone, microcrystalline Cellulose, aspartame, the withered sub-essence of the gastrodine dressing microcapsule, mannitol particles and the recipe quantity that make are crossed 30 mesh sieve uniform mixing, add magnesium stearate, tabletting, hardness are 3.56N/kg.
Embodiment 2: gastrodine tablets disintegrating in oral cavity
According to embodiment 1 same procedure, wherein disintegrating agent low substituted hydroxy-propyl fiber and crospolyvinylpyrrolidone equivalent make oral cavity disintegration tablet.
The prepared oral cavity disintegration tablet of the foregoing description all has good mouthfeel and suitable hardness.Through stability test, the result shows that also it has good stability, and meets the preparation requirement.
Embodiment 3: detect disintegration
Studies show that by the influence of temperature to disintegration time temperature is influential to measuring, temperature rising disintegrate is accelerated.37 ℃ are approached oral temperature, so select 37 ℃ of mensuration of carrying out disintegration.
The correlation research of assay method shows, the tentative disintegration time with static mode mensuration oral cavity disintegration tablet of second session summary has certain deficiency, first: when static, the disintegrate of tablet is easy to judge, but the disintegrate concluding time is difficult to determine, during disintegrate, tablet collapses diffusing, be deposited in the core surfaces of not disintegrate, can't determine when that disintegrate finishes.The second, the measurement result of disintegration time and the actual disintegration time difference in the oral cavity are bigger.When static, the disintegrate of tablet relies on self disintegration of tablet fully, and in the oral cavity, owing to be subjected to the stimulation of mannitol, the human body reflexive produces swallowing act and a large amount of salivas, when swallowing oral cavity disintegration tablet is applied bigger pressure, promotes disintegrate, therefore, when taking the time of disintegrate obviously faster than time of static disintegrating method.For this assay method to disintegration time is adjusted, adopt 2ml water, add sample, constantly the method for jolting.The destructive power that jolting produces is very little, the effect that dispute when swallowing applies tablet is compared and can be ignored, can not shorten disintegration time significantly after increasing jolting, therefore think, adopt 2ml water, the method that disintegration time is measured in jolting has better implement, and the reviewer easily grasps, and the result judges easily.
Testing result shows that be 21 seconds the disintegration of embodiment 1 prepared gastrodine tablets disintegrating in oral cavity, and be 38 seconds the disintegration of the gastrodine tablets disintegrating in oral cavity of embodiment 2.All disintegrate is molten fully in 1 minute looses.
In addition, according to embodiment 1 same ratio and method, prepare three batch samples, carry out repeated trials, the oral cavity disintegration tablet that makes detected through the disintegrate time limit, recorded disintegration in 20～22 seconds.The result shows that the operability of technology is good, has good repeatability.
The present invention is described according to preferred embodiment.Should be understood that the description of front and embodiment are just to illustrating the present invention.Under prerequisite without departing from the spirit and scope of the present invention, those skilled in the art can design multiple alternative of the present invention and improvement project, and it all should be understood to be within protection scope of the present invention.
Claims (7)
1, a kind of gastrodine tablets disintegrating in oral cavity, with gastrodine as principal agent, comprise gastrodine dressing microcapsule, diluent and disintegrating agent, it is characterized in that described gastrodine dressing microcapsule is by gastrodine and micropowder silica gel mix homogeneously, be the microcapsule that coating material is prepared from acrylic resin and ethyl cellulose again, described diluent is mannitol and microcrystalline Cellulose, described disintegrating agent is low-substituted hydroxypropyl cellulose and crospolyvinylpyrrolidone, and wherein said acrylic resin is polyacrylic resin IV and Eudragit
NE30D, and the consumption of described diluent account for sheet heavy 30%～70%, low-substituted hydroxypropyl cellulose and crospolyvinylpyrrolidone are 1: 1～2 by weight calculating.
2, gastrodine tablets disintegrating in oral cavity according to claim 1, wherein, it heavily is 50% that the consumption of described diluent accounts for sheet.
3, gastrodine tablets disintegrating in oral cavity according to claim 1 and 2 wherein, also contains binding agent, correctives, lubricant, fluidizer or effervescent.
4, a kind of method for preparing each described gastrodine tablets disintegrating in oral cavity of claim 1-3, it is characterized in that comprising the steps: (1) gastrodine and micropowder silica gel mix homogeneously, is that coating material is made the gastrodine dressing microcapsule with acrylic resin and ethyl cellulose again; (2) gastrodine dressing microcapsule and all the other component mix homogeneously carry out tabletting.
5, method according to claim 4, wherein, in the described step (2), diluent mixes with gastrodine dressing microcapsule and other component after making granule with binding agent.
6, according to claim 4 or 5 described methods, the pressure that it is characterized in that tabletting is 3～4N/kg.
7, gastrodine tablets disintegrating in oral cavity according to claim 1 wherein, calculates 50 parts of gastrodine, 10 parts of polyacrylic resin IV, Eudragit by weight
1 part of NE30D, 10 parts of ethyl celluloses, 6 parts of low-substituted hydroxypropyl celluloses, 8 parts of crospolyvinylpyrrolidone, 80 parts in mannitol, 10 parts of microcrystalline Cellulose, 5.4 parts of micropowder silica gels, 2 parts of aspartames, 2 parts of flavoring orange essences, 1.5 parts of magnesium stearate, each is an amount of for PVP-K30 and ethanol, and makes by the following method: 1. polyacrylic resin IV, Eudragit
NE30D and ethyl cellulose are dissolved in ethanol, make coating solution; 2. gastrodine and micropowder silica gel mix homogeneously are made the gastrodine dressing microcapsule with above-mentioned coating solution; 3. mannitol is made mannitol particles with PVP-K30 as binding agent; 4. the above-mentioned gastrodine dressing microcapsule that makes, mannitol particles and remaining component uniform mixing carry out tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101405208A CN100446759C (en) | 2006-10-16 | 2006-10-16 | Gastrodine tablets disintegrating in oral cavity and process for producing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101405208A CN100446759C (en) | 2006-10-16 | 2006-10-16 | Gastrodine tablets disintegrating in oral cavity and process for producing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1923185A CN1923185A (en) | 2007-03-07 |
| CN100446759C true CN100446759C (en) | 2008-12-31 |
Family
ID=37816129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101405208A Active CN100446759C (en) | 2006-10-16 | 2006-10-16 | Gastrodine tablets disintegrating in oral cavity and process for producing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100446759C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101444513B (en) * | 2007-11-27 | 2011-05-11 | 上官清 | Cefaclor orally disintegrating tablet and preparation method thereof |
| EP3541359B1 (en) * | 2016-11-18 | 2021-01-27 | Fertin Pharma A/S | Tablet comprising separate binder and erythritol |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1562053A (en) * | 2004-03-23 | 2005-01-12 | 刘智 | Gastrodine oral disintigration tablet with sedation hypnotic and analgesis function |
| CN1586495A (en) * | 2004-07-08 | 2005-03-02 | 北京阜康仁生物制药科技有限公司 | Roxithromycin oral disintegration tablet |
| CN1586485A (en) * | 2004-07-08 | 2005-03-02 | 北京阜康仁生物制药科技有限公司 | Cefaclor oral disintegration tablet |
| CN1806807A (en) * | 2005-01-18 | 2006-07-26 | 安徽省现代中药研究中心 | Gastrodine and its derivative orally quick-acting tablet including orally disintegrating tablet and dispersible tablet and preparation method thereof |
-
2006
- 2006-10-16 CN CNB2006101405208A patent/CN100446759C/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1562053A (en) * | 2004-03-23 | 2005-01-12 | 刘智 | Gastrodine oral disintigration tablet with sedation hypnotic and analgesis function |
| CN1586495A (en) * | 2004-07-08 | 2005-03-02 | 北京阜康仁生物制药科技有限公司 | Roxithromycin oral disintegration tablet |
| CN1586485A (en) * | 2004-07-08 | 2005-03-02 | 北京阜康仁生物制药科技有限公司 | Cefaclor oral disintegration tablet |
| CN1806807A (en) * | 2005-01-18 | 2006-07-26 | 安徽省现代中药研究中心 | Gastrodine and its derivative orally quick-acting tablet including orally disintegrating tablet and dispersible tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1923185A (en) | 2007-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW391880B (en) | An oral soluble type compression moulding and its preparation | |
| US20040265375A1 (en) | Orally disintegrating tablets | |
| KR101907218B1 (en) | Press-coated orally disintegrating tablets | |
| TWI659752B (en) | Oral administration preparations masking the bitter taste of silodosin | |
| WO1998002185A1 (en) | Quickly disintegrable compression-molded materials and process for producing the same | |
| CN108969490A (en) | Rapid dispersion particle, oral disnitegration tablet and method | |
| JP2000103731A (en) | Rapid disintegrative solid preparation | |
| CN101185733A (en) | Jianweixiaoshi orally disintegrating tablets and preparation method | |
| CN102218050A (en) | Pharmaceutical composition for treating depression | |
| JP2008517988A (en) | Novel pharmaceutical formulation useful in the treatment of insomnia | |
| CN101822672A (en) | Compound with metformin and repaglinide, preparation method thereof and application thereof | |
| JP2003034655A (en) | Fast degradable solid tablet | |
| CN100386071C (en) | Medicine for treating cough and chronic bronchitis | |
| CN101198327A (en) | Solid compositions for treating middle-of-the-night insomnia | |
| CN100446759C (en) | Gastrodine tablets disintegrating in oral cavity and process for producing same | |
| US20060147516A1 (en) | Taste masking system for alprazolam | |
| CN106822907B (en) | Two-phase release preparation containing racecadotril and preparation method thereof | |
| JP2003176242A (en) | Quickly disintegrable compression-molded material and method for producing the same | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN101204394A (en) | Composite containing pioglitazone HCL and repaglinide | |
| CN107582536A (en) | A kind of CBS oral cavity adherent emplastrum and preparation method thereof | |
| WO2006000137A1 (en) | Oral disintegrable tablet of notogingseng total sapoin and the preparation process thereof | |
| JPH1135486A (en) | Solid pharmaceutical preparation | |
| CN109646417A (en) | A kind of Trimetazidine sustained release tablets and preparation method thereof | |
| CN101120928B (en) | Vitamin K1 orally disintegrating tablets preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 100083 Haidian District, Xueyuan Road, No. 30, A building, room No. 15, room, room 15 Patentee after: COSCI MED-TECH Co.,Ltd. Address before: 100080, room 1410, satellite building, No. 63, Zhichun Road, Beijing, Haidian District Patentee before: COSCI MED-TECH Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20230327 Address after: 8639, Floor 6, Building 3, No. 3, Yongchang North Road, Daxing District, Beijing, 100176 Patentee after: Beijing Kexin Jurun Pharmaceutical Technology Co.,Ltd. Address before: 100083 room 15, 15 / F, block a, Tiangong building, 30 Xueyuan Road, Haidian District, Beijing Patentee before: COSCI MED-TECH Co.,Ltd. |
|
| TR01 | Transfer of patent right |